everolimus

Everolimus (SDZ-RAD) is a potent mTOR inhibitor that binds to FKBP-12. It is used alone or in combination with calcineurin inhibitors.

Everolimus-D4 is a deuterated compound of Everolimus (T1784).

Everolimus-D4 (Standard) is a reference standard of Everolimus-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Everolimus-d4 is a deuterated compound of Everolimus.

Everolimus (Standard) is a reference standard for research and analysis in studies involving Everolimus. Everolimus (SDZ-RAD) is a derivative of Rapamycin, an mTOR1 inhibitor with selective and oral activity. Everolimus exhibits immunosuppressive and antitumor activity, inhibiting tumor cell proliferation, inducing apoptosis and autophagy.

Everolimus-[13C2,D4] (Standard) is a reference standard of Everolimus-[13C2,D4] intended for quantitative analysis, quality control, and related biochemical research applications.

SAR-405 is a potent and selective PIK3C3/Vps34 inhibitor (IC50:1.2 nM; Kd:1.5 nM) that prevents autophagy and synergizes with MTOR inhibition in tumor cells. SAR405 treatment also inhibits autophagy induced either by starvation or by MTOR (mechanistic target of rapamycin) inhibition. Combining SAR405 with everolimus results in a significant synergy on the reduction of cell proliferation using renal tumor cells.